SELLAS Life Sciences Group, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $20.3M | $21.4M |
| FY2022 | — | $4.9M | $17.1M |
| FY2023 | — | $-8.0M | $2.5M |
| FY2024 | — | $9.5M | $13.9M |
| FY2025 | — | $70.9M | $71.8M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $20.3M | $21.4M |
| FY2022 | — | $4.9M | $17.1M |
| FY2023 | — | $-8.0M | $2.5M |
| FY2024 | — | $9.5M | $13.9M |
| FY2025 | — | $70.9M | $71.8M |